Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 227,035	$ 96,363
Short-term investments	1,118,847	1,228,499
Accounts receivable	42,031	36,802
Inventory	14,320	12,665
Advance payments to contract manufacturers	13,280	31,834
Other current assets	13,811	15,731
Total current assets	1,429,324	1,421,894
Long-term investments	185,900	279,119
Property, plant and equipment, net	62,307	65,665
Operating lease right-of-use assets	133,901	134,177
Goodwill	76,501	76,501
Total assets	1,887,933	1,977,356
Current liabilities:
Senior secured notes, net and interest payable	254,144	252,891
Accounts payable	21,789	19,234
Accrued compensation	22,412	11,467
Accrued clinical trial expenses	38,624	32,626
Accrued contract manufacturing expenses	8,579	7,304
Other accrued expenses	11,844	11,414
Operating lease liabilities, current portion	15,613	12,516
Deferred revenue, current portion	3,007	5,517
Other current liabilities	1,459	1,692
Total current liabilities	377,471	354,661
Operating lease liabilities, less current portion	142,297	142,730
Liability related to the sale of future royalties, net	69,185	72,020
Deferred revenue, less current portion	2,554	2,554
Total liabilities	591,507	571,965
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at March 31, 2020 or December 31, 2019	0	0
Common stock, $0.0001 par value; 300,000 shares authorized; 177,863 shares and 176,505 shares outstanding at March 31, 2020 and December 31, 2019, respectively	17	17
Capital in excess of par value	3,306,655	3,271,097
Accumulated other comprehensive loss	(6,877)	(1,005)
Accumulated deficit	(2,003,369)	(1,864,718)
Total stockholders’ equity	1,296,426	1,405,391
Total liabilities and stockholders’ equity	$ 1,887,933	$ 1,977,356